123 related articles for article (PubMed ID: 37406957)
41. Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy.
Huang D; Zhang S; Zhong T; Ren W; Yao X; Guo Y; Duan XC; Yin YF; Zhang SS; Zhang X
Oncotarget; 2016 Jul; 7(28):43616-43628. PubMed ID: 27283987
[TBL] [Abstract][Full Text] [Related]
42. Endothelial Phosphatase VE-PTP Participates in Vasculogenic Mimicry by Preventing Autophagic Degradation of VE-Cadherin.
Delgado-Bellido D; Bueno-Galera C; López-Jiménez L; Garcia-Diaz A; Oliver FJ
Front Oncol; 2020; 10():18. PubMed ID: 32117706
[TBL] [Abstract][Full Text] [Related]
43. S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer.
Liu S; Ni C; Zhang D; Sun H; Dong X; Che N; Liang X; Chen C; Liu F; Bai J; Lin X; Zhao X; Sun B
Cell Death Dis; 2019 Feb; 10(3):200. PubMed ID: 30814488
[TBL] [Abstract][Full Text] [Related]
44. Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin.
Delgado-Bellido D; Serrano-Saenz S; Fernández-Cortés M; Oliver FJ
Mol Cancer; 2017 Mar; 16(1):65. PubMed ID: 28320399
[TBL] [Abstract][Full Text] [Related]
45. Epigallocatechin-3-Gallate Suppresses Vasculogenic Mimicry through Inhibiting the Twist/VE-Cadherin/AKT Pathway in Human Prostate Cancer PC-3 Cells.
Yeo C; Han DS; Lee HJ; Lee EO
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936664
[TBL] [Abstract][Full Text] [Related]
46. Metastasis-associated in colon cancer-1 promotes vasculogenic mimicry in gastric cancer by upregulating TWIST1/2.
Wang L; Lin L; Chen X; Sun L; Liao Y; Huang N; Liao W
Oncotarget; 2015 May; 6(13):11492-506. PubMed ID: 25895023
[TBL] [Abstract][Full Text] [Related]
47. cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer.
Tang J; Wang J; Fan L; Li X; Liu N; Luo W; Wang J; Wang Y; Wang Y
Oncotarget; 2016 Apr; 7(17):24050-62. PubMed ID: 26992227
[TBL] [Abstract][Full Text] [Related]
48. cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer.
Wang Y; Tong L; Wang J; Luo J; Tang J; Zhong L; Xiao Q; Niu W; Li J; Zhu J; Chen H; Li X; Wang Y
Acta Biomater; 2019 Aug; 94():495-504. PubMed ID: 31252171
[TBL] [Abstract][Full Text] [Related]
49. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
[TBL] [Abstract][Full Text] [Related]
50. GOLPH3 Promotes Vasculogenic Mimicry via the Epithelial Mesenchymal Transition in Glioblastoma Cells.
Jia J; Chu L; Zeng X; Long N; Dong M; Yang Y; Hu Y; Liu J
Turk Neurosurg; 2023; 33(5):722-730. PubMed ID: 35023138
[TBL] [Abstract][Full Text] [Related]
51. Dual VEGF/PDGF knockdown suppresses vasculogenic mimicry formation in choroidal melanoma cells via the Wnt5a/β-catenin/AKT signaling pathway.
Yuan Y; Geng B; Xu X; Zhao H; Bai J; Dou Z; Jia S; Yu X; Luo W
Acta Histochem; 2022 Jan; 124(1):151842. PubMed ID: 34995928
[TBL] [Abstract][Full Text] [Related]
52. Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets.
Mao JM; Liu J; Guo G; Mao XG; Li CX
Biomark Res; 2015; 3():8. PubMed ID: 26085929
[TBL] [Abstract][Full Text] [Related]
53. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications.
Kirschmann DA; Seftor EA; Hardy KM; Seftor RE; Hendrix MJ
Clin Cancer Res; 2012 May; 18(10):2726-32. PubMed ID: 22474319
[TBL] [Abstract][Full Text] [Related]
54. MicroRNA-204/CREB5 axis regulates vasculogenic mimicry in breast cancer cells.
Contreras-Sanzón E; Palma-Flores C; Flores-Pérez A; M Salinas-Vera Y; B Silva-Cázares M; A Marchat L; G Avila-Bonilla R; N Hernández de la Cruz O; E Álvarez-Sánchez M; Pérez-Plasencia C; D Campos-Parra A; López-Camarillo C
Cancer Biomark; 2022; 35(1):47-56. PubMed ID: 35662106
[TBL] [Abstract][Full Text] [Related]
55. Dual antivascular function of human fibulin-3 variant, a potential new drug discovery strategy for glioblastoma.
Ke C; Luo JR; Cen ZW; Li Y; Cai HP; Wang J; Chen FR; Siegel ER; Le KN; Winokan JR; Gibson GJ; McSwain AE; Afrasiabi K; Linskey ME; Zhou YX; Chen ZP; Zhou YH
Cancer Sci; 2020 Mar; 111(3):940-950. PubMed ID: 31922633
[TBL] [Abstract][Full Text] [Related]
56. Vasculogenic mimicry: current status and future prospects.
Zhang S; Zhang D; Sun B
Cancer Lett; 2007 Sep; 254(2):157-64. PubMed ID: 17306454
[TBL] [Abstract][Full Text] [Related]
57. All-trans retinoic acid impairs the vasculogenic mimicry formation ability of U87 stem-like cells through promoting differentiation.
Ling GQ; Liu YJ; Ke YQ; Chen L; Jiang XD; Jiang CL; Ye W
Mol Med Rep; 2015 Jul; 12(1):165-72. PubMed ID: 25760394
[TBL] [Abstract][Full Text] [Related]
58. Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas.
Scully S; Francescone R; Faibish M; Bentley B; Taylor SL; Oh D; Schapiro R; Moral L; Yan W; Shao R
J Neurosci; 2012 Sep; 32(37):12950-60. PubMed ID: 22973019
[TBL] [Abstract][Full Text] [Related]
59. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry.
Sun T; Zhao N; Zhao XL; Gu Q; Zhang SW; Che N; Wang XH; Du J; Liu YX; Sun BC
Hepatology; 2010 Feb; 51(2):545-56. PubMed ID: 19957372
[TBL] [Abstract][Full Text] [Related]
60. MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of
Liu W; Lv C; Zhang B; Zhou Q; Cao Z
RNA; 2017 Jul; 23(7):1019-1027. PubMed ID: 28396577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
